Compare Stocks

→ Dems have chosen Biden replacement? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$0.94 +2.2%	$1.01	$0.74 ▼ $1.76	$37.49M	1.25	214,561 shs	205,541 shs
INKT MiNK Therapeutics	$0.90	$0.96	$0.75 ▼ $3.34	$31.23M	0.04	55,778 shs	20,100 shs
TARA Protara Therapeutics	$3.00 +0.7%	$3.44	$1.04 ▼ $5.24	$61.77M	1.8	290,105 shs	922,419 shs
TVGN Tevogen Bio	$0.98 -1.0%	$3.32	$0.80 ▼ $21.09	$15.58M	0.49	714,795 shs	2.40 million shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	+2.34%	+16.97%	+14.70%	+0.01%	-1.16%
INKT MiNK Therapeutics	-1.25%	-8.16%	-10.00%	-1.10%	-40.40%
TARA Protara Therapeutics	+0.67%	+3.09%	-5.96%	-1.64%	-7.98%
TVGN Tevogen Bio	-0.70%	+1.49%	-59.82%	+98,449,900.00%	+98,449,900.00%

Dems have chosen Biden replacement? (Ad)

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

See who it is HERE.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	2.8859 of 5 stars	3.0	5.0	0.0	0.0	2.9	0.8	1.3
INKT MiNK Therapeutics	2.1262 of 5 stars	3.5	3.0	0.0	0.0	2.4	0.8	0.6
TARA Protara Therapeutics	1.5804 of 5 stars	3.5	2.0	0.0	0.0	2.4	1.7	0.0
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	2.00	Hold	$4.00	325.49% Upside
INKT MiNK Therapeutics	3.00	Buy	$9.00	900.00% Upside
TARA Protara Therapeutics	3.00	Buy	$26.50	783.33% Upside
TVGN Tevogen Bio	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TVGN, TARA, INKT, and ACHL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/6/2024	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
4/22/2024	TARA Protara Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $30.00
4/8/2024	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
4/5/2024	ACHL Achilles Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $6.00
4/5/2024	ACHL Achilles Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$8.00 ➝ $2.00
3/21/2024	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $9.00
3/14/2024	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00

(Data available from 5/11/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.27 per share	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($0.52) per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($1.10) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.60	N/A	N/A	N/A	N/A	-42.95%	-37.88%	8/2/2024 (Estimated)
INKT MiNK Therapeutics	-$22.46M	-$0.66	N/A	N/A	N/A	N/A	N/A	-220.64%	N/A
TARA Protara Therapeutics	-$40.42M	-$3.74	N/A	N/A	N/A	N/A	-58.80%	-51.37%	8/1/2024 (Estimated)
TVGN Tevogen Bio	-$70K	N/A	0.00	∞	N/A	N/A	-21.83%	-0.28%	N/A

Latest TVGN, TARA, INKT, and ACHL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/4/2024	Q4 2023	ACHL Achilles Therapeutics	N/A	-$0.46	-$0.46	-$0.46	N/A	N/A
3/21/2024	Q4 2023	INKT MiNK Therapeutics	-$0.15	-$0.16	-$0.01	-$0.16	N/A	N/A
3/13/2024	Q4 2023	TARA Protara Therapeutics	-$1.03	-$0.90	+$0.13	-$0.90	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	9.63	8.57
INKT MiNK Therapeutics	N/A	0.32	0.32
TARA Protara Therapeutics	N/A	10.53	10.53
TVGN Tevogen Bio	N/A	0.12	0.12

Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
INKT MiNK Therapeutics	2.87%
TARA Protara Therapeutics	38.13%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
INKT MiNK Therapeutics	17.81%
TARA Protara Therapeutics	18.40%
TVGN Tevogen Bio	56.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	204	39.88 million	37.73 million	Not Optionable
INKT MiNK Therapeutics	31	34.70 million	28.52 million	No Data
TARA Protara Therapeutics	26	20.59 million	9.33 million	Optionable
TVGN Tevogen Bio	17	15.82 million	6.86 million	N/A

TVGN, TARA, INKT, and ACHL Headlines

Source	Headline
	Tevogen Bio Inc: Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives finanznachrichten.de - May 11 at 6:50 AM
	Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives globenewswire.com - May 10 at 5:40 PM
	Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives globenewswire.com - May 1 at 8:05 AM
	Tevogen Bio Inc: Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments finanznachrichten.de - April 27 at 2:20 AM
	Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments globenewswire.com - April 26 at 9:23 AM
	U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.98% msn.com - April 26 at 2:04 AM
	Tevogen Bio Holdings Inc TVGN morningstar.com - April 20 at 5:36 PM
	Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session msn.com - April 16 at 8:17 AM
	Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers finance.yahoo.com - April 11 at 12:52 PM
	Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers globenewswire.com - April 11 at 8:05 AM
	TVGN Tevogen Bio Holdings Inc. seekingalpha.com - April 5 at 11:11 PM
	Why Is Tevogen Bio (TVGN) Stock Up 46% Today? investorplace.com - April 4 at 10:12 AM
	Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development globenewswire.com - April 3 at 8:05 AM
	Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price globenewswire.com - March 28 at 8:05 AM
	Tevogen Bio Announces Series A-1 Preferred Stock Investment globenewswire.com - March 27 at 9:20 AM
	Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant businesswire.com - March 20 at 7:00 AM
	Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI businesswire.com - February 27 at 4:39 PM
	Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment businesswire.com - February 21 at 7:00 AM
	Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market businesswire.com - February 17 at 12:17 AM
	Tevogen Bio Announces $8 Million Equity Investment businesswire.com - February 15 at 9:25 AM
	Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN globenewswire.com - February 14 at 3:55 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Achilles Therapeutics

NASDAQ:ACHL

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

MiNK Therapeutics

NASDAQ:INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Protara Therapeutics

NASDAQ:TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Tevogen Bio

NASDAQ:TVGN

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial